jeudi 26 juillet 2018

Onco Actu du 26 juillet 2018

3.2 Prévention - Obésité

Obesity at record high in children aged 10-11 years [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

In New Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma [ASCO]

4.10 Dép., diag. & prono. - Poumon

Dogs’ sensitive noses may be the key to early detection of lung cancer [The Conversation]

5. Traitements

De-intensifying treatment for early thyroid cancer [STAT]

5.1 Traitements - Pré-clinique

New strategy for cancer therapy spells double trouble for tumors [Sripps Research Institute]

Protein discovery may explain why some patients develop resistance to new class of anti-cancer drugs [University of Cambridge]

Turbo-charging chemotherapy for lung cancer [Garvan Institute]

5.10 Traitements - Essais

Takeda's also-ran ALK drug Alunbrig aims to challenge Pfizer with new first-line data [FiercePharma]

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve [Takeda]

5.12.5 Immunothérapies - Pharma

Merck's Keytruda shores up head and neck case with first-line trial win [FiercePharma]

Merck claims a needed win for Keytruda with interim OS data in head and neck cancer [EndPoints]

KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20) [Merck]

5.12.7 Immunothérapies - vaccins

Making Personalized Cancer Vaccines Takes an Army—of Robots [Wired]

5.2 Pharma

AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures [FierceBiotech]

5.2.1 Pharma - Partenariats

A Note On 23andMe’s New Collaboration with GSK [23andMe Blog]

GlaxoSmithKline makes $300M investment in 23andMe, forms 50-50 R&D pact [FierceBiotech]

23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs [Forbes]

5.3 Traitements - FDA, EMA, NICE...

FDA Publishes List of Surrogate Endpoints Used in Drug Approvals [RAPS]

Implementing the 21st Century Cures Act: An Update from FDA and NIH - Oral Statement [FDA]

5.4 Traitements - Economie

Paying for therapies that cure: innovative solutions needed [STAT]

Pembrolizumab for classical hodgkin lymphoma [NICE]

NICE Recommends Pembrolizumab for Untreated PD-L1-positive Metastatic NSCLC [ESMO]

6.6 Publications

Third Retraction for Harvard Cancer Biologist [The Scientist]

Nature cancer paper that raised animal welfare concerns is retracted [Retraction Watch]

6.7 DMP, Big Data & applis

Ex-Apple Health director is now working to fix medical records [CNBC]